Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Baxter
Medtronic
Johnson and Johnson

Last Updated: September 25, 2022

PIZENSY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Pizensy patents expire, and what generic alternatives are available?

Pizensy is a drug marketed by Braintree Labs and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in PIZENSY is lactitol. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lactitol profile page.

DrugPatentWatch® Generic Entry Outlook for Pizensy

Pizensy will be eligible for patent challenges on February 12, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2025. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for PIZENSY
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in PIZENSY?PIZENSY excipients list
DailyMed Link:PIZENSY at DailyMed
Drug patent expirations by year for PIZENSY
DrugPatentWatch® Estimated Generic Entry Opportunity Date for PIZENSY
Generic Entry Date for PIZENSY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
FOR SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for PIZENSY

US Patents and Regulatory Information for PIZENSY

PIZENSY is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIZENSY is See Plans and Pricing.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting PIZENSY


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

FDA Regulatory Exclusivity protecting PIZENSY

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree Labs PIZENSY lactitol FOR SOLUTION;ORAL 211281-001 Feb 12, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Braintree Labs PIZENSY lactitol FOR SOLUTION;ORAL 211281-001 Feb 12, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
AstraZeneca
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.